Sanofi Details CEO Paul Hudson’s February 2026 Departure Terms and Equity Awards
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Sanofi ( (SNY) ).
Sanofi disclosed that Chief Executive Officer Paul Hudson’s mandate ended on February 17, 2026, and that he resigned as a director on February 18, 2026, receiving no specific compensation for his board role. The company detailed that his fixed salary for 2026 and his annual variable compensation for both 2025 and the portion of 2026 served will be paid pro rata, subject to shareholder approval at upcoming annual meetings.
The filing also clarified that Hudson’s 2025 variable pay was set at €2.616 million based on a 109% achievement rate of performance targets, correcting an earlier disclosure error that had shown a 100% rate. Sanofi confirmed that he will not receive new 2026 performance shares but will retain, on a prorated basis and subject to performance, performance share awards granted in 2023, 2024, and 2025, with the 2023 grant vesting into 75,206 shares and his participation in the company’s top-up pension plan ceasing upon departure.
The most recent analyst rating on (SNY) stock is a Hold with a $57.00 price target. To see the full list of analyst forecasts on Sanofi stock, see the SNY Stock Forecast page.
Spark’s Take on SNY Stock
According to Spark, TipRanks’ AI Analyst, SNY is a Outperform.
The score is driven primarily by solid financial resilience and a constructive earnings outlook (growth, margin expansion, and buybacks). Valuation is supportive with a reasonable P/E and strong dividend, while weaker technical trend signals (below major moving averages and negative MACD) temper the overall rating.
To see Spark’s full report on SNY stock, click here.
More about Sanofi
Sanofi is a global pharmaceutical company based in Paris that develops, manufactures, and markets prescription medicines, vaccines, and consumer healthcare products. The group focuses on innovative therapies across specialty care, vaccines, and general medicines, with a significant presence in major global healthcare markets and a strong emphasis on research-driven growth.
Average Trading Volume: 3,795,961
Technical Sentiment Signal: Hold
Current Market Cap: $112.6B
See more data about SNY stock on TipRanks’ Stock Analysis page.
